ReviewCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2008
The role of the BRCA2 gene in susceptibility to prostate cancer revisited.
Review in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A Large-Scale Association Study Detects Novel Rare Variants, Risk Genes, Functional Elements, and Polygenic Architecture of Prostate Cancer Susceptibility.Cancer research · 2021Article
- Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.Cellular and molecular life sciences : CMLS · 2020Review
- Review
- Prevalence and clinical significance of pathogenic germlineCancer biology & medicine · 2019Article
- Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.Human mutation · 2018Article
- Update on Screening for Urological Malignancies.Rambam Maimonides medical journal · 2017Review
- Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.Transactions of the American Clinical and Climatological Association · 2017Article
- Translational and clinical implications of the genetic landscape of prostate cancer.Nature reviews. Clinical oncology · 2016Review
- Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.Medical oncology (Northwood, London, England) · 2015Article
- Elevated risk of prostate cancer among men with Lynch syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.Prostate cancer · 2013Article
- Germline mutations in HOXB13 and prostate-cancer risk.The New England journal of medicine · 2012Article
- The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2011Article
- Cancer biomarker discovery: the entropic hallmark.PloS one · 2010Article
- Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study.Cancer causes & control : CCC · 2010Article
- Cancer risk assessment for the primary care physician.Primary care · 2009Article
- No evidence of BRCA2 mutations in chromosome 13q-linked Utah high-risk prostate cancer pedigrees.BMC research notes · 2009Article
- Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics.Cancer genomics & proteomicsArticle
- The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Prostate cancer is a genetically complex disease with multiple predisposing factors affecting presentation, progression, and outcome. Epidemiologic studies have long shown an aggregation of breast and prostate cancer in some families. More recently, studies have reported an apparent excess of prostate cancer cases among BRCA2 mutation-carrying families. Additionally, population-based screens of early-onset prostate cancer patients have suggested that the prevalence of deleterious BRCA2 mutations in this group is 1% to 2%, imparting a significantly increased risk of the disease compared with noncarrier cases. However, studies of high-risk prostate cancer families suggest that BRCA2 plays at most a minimal role in these individuals, highlighting the potential genetic heterogeneity of the disease. In this commentary, we review the current literature and hypotheses surrounding the relationship between BRCA2 mutations and susceptibility to prostate cancer and speculate on the potential for involvement of additional genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.